Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2019, JLS Fund is a New York-based venture capital firm specializing in healthcare and biotech. The fund focuses on neuromedicine, particularly in addressing neuropsychiatric disorders. JLS Fund has a portfolio of six companies and aims to support innovative solutions in mental health.
JLS Fund invests in pre-seed, seed, Series A, and growth equity stages, with a particular emphasis on neuromedicine. The firm targets companies that address critical unmet needs in neuropsychiatric disorder treatments, including innovative therapies and infrastructure.
Notable portfolio companies include Enthea, which provides access to psychedelic-assisted therapy; ProNovo, developing precision treatments for neuropsychiatric disorders; Psilera Bioscience, focusing on psychoactive natural products; Tripp, a wellness platform; Immunis Biomedical, working on biologics for age-related diseases; and Gilgamesh, aiming to transform psychiatric disease treatment.
Email info@jls.fund with your deck to pitch JLS Fund.
Yes, JLS Fund often leads investment rounds, particularly in the pre-seed and seed stages.
JLS Fund is open to follow-on investments, especially for companies that demonstrate significant progress and alignment with their thesis.
The specific size of JLS Fund's current fund is not publicly disclosed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.